Brief: Anaptys To Announce Top-Line Data From Phase 2B Trial Of Rosnilimab, A PD-1 Depleter And Agonist, In Rheumatoid Arthritis
11/02/2025 22:47
Feb 11 (Reuters) - AnaptysBio Inc ANAB.O :
* ANAPTYS TO ANNOUNCE TOP-LINE DATA FROM PHASE 2B TRIAL OF
ROSNILIMAB, A PD-1 DEPLETER AND AGONIST, IN RHEUMATOID ARTHRITIS
ON FEB. 12, 2025
Source text: ID:nGNX2ssLQQ
Further company coverage: ANAB.O
Recent news on AnaptysBio
See all newsU.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged